Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial

Diabetes Care

Volumn 36, Issue 5, 2013, Pages 1266-1271

  Gerstein, Hertzel C ^a   Ambrosius, Walter T ^b   Danis, Ronald ^c   Ismail Beigi, Faramarz ^d   Cushman, William ^e   Calles, Jorge ^f   Banerji, Maryann ^g   Schubart, Ulrich ^h   Chew, Emily Y ⁱ  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁱ NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEREOSCOPIC VISION; SYSTOLIC BLOOD PRESSURE; VITRECTOMY;

AGED; CARDIOVASCULAR DISEASES; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84876792928     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1311     Document Type: Article

References (20)

1. Cusick M, Meleth AD, Agrón E, et al.; Early Treatment Diabetic Retinopathy Study Research Group. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: Early Treatment Diabetic Retinopathy Study report no. 27. Diabetes Care 2005; 28:617-625 (Pubitemid 40315322)
2. Miettinen H, Haffner SM, Lehto S, Rönnemaa T, Pyörä là K, Laakso M. Reti-nopathy predicts coronary heart disease events in NIDDM patients. Diabetes Care 1996;19:1445-1448 (Pubitemid 26418633)
3. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol 1999;117:1487-1495 (Pubitemid 29536476)
4. Wong TY, Klein R, Couper DJ, et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 2001;358: 1134-1140 (Pubitemid 32971846)
5. van Hecke MV, Dekker JM, Stehouwer CD, et al.; EURODIAB prospective complications study. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 2005;28:1383-1389 (Pubitemid 40756701)
6. Reaven PD, Emanuele N, Moritz T, et al.; Veterans Affairs Diabetes Trial. Pro-liferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2008;31:952-957
7. McGeechan K, Liew G, Macaskill P, et al. Risk prediction of coronary heart disease based on retinal vascular caliber (from the Atherosclerosis Risk In Communities [ARIC] Study). Am J Cardiol 2008;102: 58-63
8. Targher G, Bertolini L, Zenari L, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabet Med 2008;25:45-50
9. Cheung N, Wong TY. Diabetic retinopa-thy and systemic vascular complications. Prog Retin Eye Res 2008;27:161-176
10. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopa-thy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care 2011;34:1238-1244
11. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559 (Pubitemid 351831356)
12. Chew EY, Ambrosius WT, Howard LT, et al.; ACCORD Study Group. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol 2007;99(12A):103i-111i
13. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363: 233-244
14. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362: 1575-1585
15. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict mac-rovascular events in type 2 diabetes? Atherosclerosis 2011;218:13-18
16. Ritman EL, Lerman A. The dynamic vasa vasorum. Cardiovasc Res 2007;75:649-658 (Pubitemid 47238745)
17. Mulligan-Kehoe MJ. The vasa vasorum in diseased and nondiseased arteries. Am J Physiol Heart Circ Physiol 2010;298: H295-H305
18. Nathan DM, Lachin J, Cleary P, et al.; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-2303 (Pubitemid 36638103)
19. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653 (Pubitemid 41817713)
20. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589